Q2 2023 results - Tuesday, July 18, 2023

Media release:

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Interim financial report (PDF 0.5 MB)


Watch the webcast

Download the interactive presentation (PDF 2.9 MB)

Download the podcast (MP3 34 MB)

Read the transcript

Novartis Q2 2023 Impact and Sustainability Update (PDF 0.3 MB)
 

Key figures1 Q2 2023
(USD m)
Q2 2022
(USD m)
% change
(USD/cc)
Net sales 13,622 12,781 7 (cc: 9)
Operating income 2,920 2,228 31 (cc: 50)
Net income 2,317 1,695 37 (cc: 54)
EPS (USD) 1.11 0.77 44 (cc: 62)
Free cash flow2 3,275 3,498 -6

Core
     
Operating income 4,668 4,270 9 (cc: 17)
Net income 3,811 3,431 11 (cc: 19)
EPS (USD) 1.83 1.56 17 (cc: 25)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. Effective January 1, 2023, Novartis revised its definition of free cash flow, to define free cash flow as net cash flows from operating activities less purchases of property, plant and equipment. To aid in comparability, the prior year free cash flow amounts have been revised to conform with the new free cash flow definition. See page 48 of the Condensed Interim Financial Report.

Q1 2023 results - Tuesday, April 25, 2023

Media release:

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Interim financial report (PDF 0.3 MB)


Watch the webcast

Download the interactive presentation (PDF 3.4 MB)

Download the podcast (MP3 34 MB)

Read the presentation transcript

Novartis Q1 2023 Impact and Sustainability Update (PDF 1.9 MB)
 

Key figures1 Q1 2023
(USD m)
Q1 2022
(USD m)
% change
(USD/cc)
Net sales 12,953 12,531 3 (cc: 8)
Operating income 2,856 2,852 0 (cc: 9)
Net income 2,294 2,219 3 (cc: 14)
EPS (USD) 1.09 1.00 9 (cc: 20)
Free cash flow2 2,720 1,392 95

Core
     
Operating income 4,413 4,083 8 (cc: 15)
Net income 3,614 3,251 11 (cc: 18)
EPS (USD) 1.71 1.46 17 (cc: 25)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. Effective January 1, 2023, Novartis revised its definition of free cash flow, to define free cash flow as net cash flows from operating activities less purchases of property, plant and equipment. To aid in comparability, the prior year free cash flow amounts have been revised to conform with the new free cash flow definition. See page 35 of the Condensed Interim Financial Report.

 

Annual results and Q4 2022
Wednesday, February 01, 2023

Media release:

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)


Watch the webcast

Download the presentation (PDF 5.1 MB)

Download the podcast (MP3 45 MB)

Read the presentation transcript

Novartis ESG Update Q4 2022 (PDF 0.9 MB)
 

Key figures1 Q4 2022
(USD m)
Q4 2021
(USD m)
% change
(USD/cc)
Net sales 12,690 13,229 -4 (cc: 3)
Operating income 1,949 2,562 -24 (cc: -14)
Net income 1,466 16,306 -91 (cc: -90)
EPS (USD) 0.69 7.29 -91 (cc: -89)
Free cash flow 3,552 3,027 17

Core
     
Operating income 4,030 3,819 6 (cc: 15)
Net income 3,251 3,135 4 (cc: 14)
EPS (USD) 1.52 1.40 9 (cc: 19)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Q3 2022 results - Tuesday, October 25, 2022

Media release:

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Interim financial report (PDF 0.5 MB)


Watch the webcast

Download the presentation (PDF 3.7 MB)

Download the podcast (MP3 40 MB)

Read the presentation transcript

Novartis ESG Update - October 31, 2022 (PDF 0.5 MB)
 

Key figures1 Q3 2022
(USD m)
Q3 2021
(USD m)
% change
(USD/cc)
Net sales 12,543 13,030 -4 (cc: 4)
Operating income 2,168 3,233 -33 (cc: -23)
Net income 1,575 2,758 -43 (cc: -33)
EPS (USD) 0.73 1.23 -41 (cc: -31)
Free cash flow 4,169 4,423 -6

Core
     
Operating income 4,282 4,467 -4 (cc: 5)
Net income 3,419 3,830 -11 (cc: -2)
EPS (USD) 1.58 1.71 -8 (cc: 1)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

2022 Quarterly Results

Q2 2022 Media Release (PDF 0.2 MB)

Q2 2022 Financial Report (PDF 0.5 MB)

Q1 2022 Media Release (PDF 0.2 MB)

Q1 2022 Financial Report (PDF 0.4 MB)

2021 Quarterly Results

Q4 2021 Media Release (PDF 0.3 MB)

Q4 2021 Financial Report (PDF 0.5 MB)

Reconciliation of 2021 results excluding Roche investment impacts (PDF 0.5 MB)

Q3 2021 Media Release (PDF 0.3 MB)

Q3 2021 Financial Report (PDF 0.5 MB)

Q2 2021 Media Release (PDF 0.4 MB)

Q2 2021 Financial Report (PDF 0.5 MB)

Q1 2021 Media Release (PDF 0.2 MB)

Q1 2021 Financial Report (PDF 0.4 MB)

2020 Quarterly Results

Q4 2020 Media Release (PDF 0.2 MB)

Q4 2020 Financial Report (PDF 0.9 MB)

Q3 2020 Media Release (PDF 0.2 MB)

Q3 2020 Financial Report (PDF 0.8 MB)

Q2 2020 Media Release (PDF 0.1 MB)

Q2 2020 Financial Report (PDF 0.8 MB)

Q1 2020 Media Release (PDF 0.2 MB)

Q1 2020 Financial Report (PDF 0.6 MB)

2019 Quarterly Results

Q4 2019 Media Release (PDF 0.1 MB)

Q4 2019 Financial Report (PDF 0.7 MB)

Q3 2019 Media Release (PDF 0.1 MB)

Q3 2019 Financial Report (PDF 0.8 MB)

Q2 2019 Media Release (PDF 0.2 MB)

Q2 2019 Financial Report (PDF 0.6 MB)

Q1 2019 Media Release (PDF 0.5 MB)

Q1 2019 Financial Report (PDF 0.5 MB)

2018 Quarterly Results

Q4 2018 Media Release (PDF 0.1 MB)

Q4 2018 Financial Report (PDF 0.6 MB)

Q3 2018 Media Release (PDF 0.1 MB)

Q3 2018 Financial Report (PDF 0.7 MB)

Q2 2018 Media Release (PDF 0.1 MB)

Q2 2018 Financial Report (PDF 0.5 MB)

Q1 2018 Media Release (PDF 0.1 MB)

Q1 2018 Financial Report (PDF 0.5 MB)

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.